A4978

Applied Filters:

Keyword:'A4978'

Showing 1-30 of 87 results for "A4978" within Papers

Current state of orthodontic patients under bisphosphonate therapy.

Elena Krieger et al.

Head & face medicine, 9, 10-10 (2013-04-06)

Bisphosphonates are a common medication for the prevention and therapy of osteoporosis, but are also applied for tumor diseases. They affect bone metabolism, and therefore also orthodontic treatments, but how it does has yet not been definitively clarified. Therefore, the

Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time.

S Uchiyama et al.

The bone & joint journal, 95-B(11), 1544-1550 (2013-10-24)

This multicentre prospective clinical trial aimed to determine whether early administration of alendronate (ALN) delays fracture healing after surgical treatment of fractures of the distal radius. The study population comprised 80 patients (four men and 76 women) with a mean

Effect of local vs. systemic bisphosphonate delivery on dental implant fixation in a model of osteonecrosis of the jaw.

J Abtahi et al.

Journal of dental research, 92(3), 279-283 (2012-12-25)

Locally applied bisphosphonates may improve the fixation of metal implants in bone. However, systemic bisphosphonate treatment is associated with a risk of osteonecrosis of the jaw (ONJ). We hypothesized that local delivery of bisphosphonate from the implant surface improves the

Effect of bisphosphonates on the rapidly growing male murine skeleton.

Eric D Zhu et al.

Endocrinology, 155(4), 1188-1196 (2014-01-16)

Bisphosphonates are effective for preventing and treating skeletal disorders associated with hyperresorption. Their safety and efficacy has been studied in adults where the growth plate is fused and there is no longitudinal bone growth and little appositional growth. Although bisphosphonate

Alendronate attenuates eosinophilic airway inflammation associated with suppression of Th2 cytokines, Th17 cytokines, and eotaxin-2.

Oh Sasaki et al.

Journal of immunology (Baltimore, Md. : 1950), 191(6), 2879-2889 (2013-08-13)

Bisphosphonates (BPs) have been widely used to treat osteoporosis. They act by inhibiting farnesyl diphosphate synthase in the mevalonate pathway. This resembles the action of statins, whose immune-modulating effect has recently been highlighted. In contrast, the effect of BPs on

Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness.

Hee Yeon Kim et al.

Experimental & molecular medicine, 50(10), 1-12 (2018-10-20)

Glioblastoma is a highly malignant tumor that easily acquires resistance to treatment. The stem-cell-like character (stemness) has been thought to be closely associated with the treatment resistance of glioblastoma cells. In this study, we determined that farnesyl diphosphate synthase (FDPS)

An in vitro assessment of fibroblast and osteoblast response to alendronate-modified titanium and the potential for decreasing fibrous encapsulation.

Xuefeng Hu et al.

Tissue engineering. Part A, 19(17-18), 1919-1930 (2013-04-02)

Fibrous encapsulation can impair implant osseointegration and cause implant failure but currently there are limited strategies to address this problem. Since bisphosphonates (BPs), a class of drugs widely used to treat bone diseases, was recently found to induce fibroblast apoptosis

μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy.

Chantal M J de Bakker et al.

Bone, 73, 198-207 (2015-01-03)

Current osteoporosis treatments improve bone mass by increasing net bone formation: anti-resorptive drugs such as bisphosphonates block osteoclast activity, while anabolic agents such as parathyroid hormone (PTH) increase bone remodeling, with a greater effect on formation. Although these drugs are

MR findings in the arthropathy of relapsing polychondritis.

Ivan R Rohena-Quinquilla et al.

Pediatric radiology, 43(9), 1221-1226 (2013-04-16)

We report a case of relapsing polychondritis involving three synovial joints in a child. Initial presentation was at 5 years of age with periorbital edema and chemosis of the conjunctiva with a definite diagnosis established at 9 years of age

Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats.

K Hatori et al.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 26(1), 303-313 (2014-09-23)

Mechanical loading at high frequency affects bone. Whether this also applies to osteoporotic bone, combined or not with bisphosphonate therapy, was investigated in this animal study through imaging. An anabolic effect of high-frequency loading on osteoporotic bone, however non-synergistic with

Effect of a 300 000-IU loading dose of ergocalciferol (Vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency.

C Turner et al.

The Journal of clinical endocrinology and metabolism, 98(2), 550-556 (2013-01-04)

Several trials have reported an increased risk of fractures and falls after intermittent high-dose vitamin D. Treatment with loading doses of vitamin D may increase 1,25(OH)(2) vitamin D catabolism through changes in calcium/phosphate homeostasis and fibroblast growth factor-23 (FGF-23). The

Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.

J A Meganck et al.

Bone, 56(1), 204-212 (2013-06-19)

Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by increased skeletal fragility. Patients are often treated with bisphosphonates to attempt to reduce fracture risk. However, bisphosphonates reside in the skeleton for many years and long-term administration may impact bone

Bone density and bone turnover marker monitoring after discontinuation of alendronate therapy: an evidence-based decision to do less.

Margaret L Gourlay et al.

JAMA internal medicine, 174(7), 1134-1135 (2014-05-07)

Pharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation.

Virginie Vives et al.

Nature communications, 6, 6218-6218 (2015-02-04)

Osteoporosis is caused by excessive activity of bone-degrading osteoclasts over bone-forming osteoblast. Standard antiosteolytic treatments inhibit bone resorption by inducing osteoclast loss, with the adverse effect of hindering also bone formation. Formation of the osteoclast sealing zone requires Dock5, a

A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study.

Wen-Yuan Lee et al.

PloS one, 7(12), e53032-e53032 (2013-01-10)

Controversy still exists regarding whether alendronate (ALN) use increases the risk of esophageal cancer or breast cancer. This paper explores the possible association between the use of oral ALN in osteoporosis patients and subsequent cancer risk using the National Health

Bisphosphonates do not reduce breast cancer in postmenopausal women.

Aju Mathew et al.

Annals of internal medicine, 162(2), JC5-JC5 (2015-01-20)

Atypical femoral fractures associated with long-term bisphosphonate use.

Soumya Chatterjee

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 185(14), 1248-1248 (2013-05-08)

High-frequency loading positively impacts titanium implant osseointegration in impaired bone.

M Chatterjee et al.

High-frequency loading via whole body vibration promotes bone formation and increases bone strength. Whether this translates to positive titanium implant osseointegration in osteoporotic bone was explored in this animal study. An anabolic effect of not only bisphosphonate treatment but also

Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial.

Shmuel Banai et al.

American heart journal, 165(2), 234-240 (2013-01-29)

Activation of systemic innate immunity is critical in the chain of events leading to restenosis. LABR-312 is a novel compound that transiently modulates circulating monocytes, reducing accumulation of these cells at vascular injury sites and around stent struts. The purpose

Alendronate alleviates the symptoms of experimental autoimmune encephalomyelitis.

Kyungsook Jung et al.

International immunopharmacology, 84, 106534-106534 (2020-05-04)

Nitrogen-containing bisphosphonates, such as alendronate, have been widely used to treat osteoporosis because they may target multiple signals in the mevalonate cascade. The present study evaluated the therapeutic effects of alendronate on experimental autoimmune encephalomyelitis (EAE), which is a prototypical

The effect of alendronate-loaded polycarprolactone nanofibrous scaffolds on osteogenic differentiation of adipose-derived stem cells in bone tissue regeneration.

Young-Pil Yun et al.

Journal of biomedical nanotechnology, 10(6), 1080-1090 (2014-04-23)

The osteogenic effect of culturing adipose-derived stem cells (ADSCs) on alendronate (Aln)-loaded polycarprolactone (PCL) nanofibrous scaffolds was evaluated by examining alkaline phosphatase (ALP) activity, calcium content, and expression of osteogenic differentiation genes in vitro. The 10% Aln/PCL nanofibrous scaffolds showed

The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene.

Qiaoli Li et al.

Cell cycle (Georgetown, Tex.), 14(7), 1082-1089 (2015-01-22)

Pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy (GACI) are heritable ectopic mineralization disorders. Most cases of PXE and many cases of GACI harbor mutations in the ABCC6 gene. There is no effective treatment for these disorders. We explored

High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major.

Ratna Chatterjee et al.

British journal of haematology, 166(2), 292-294 (2014-03-19)

Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.

Miguel Angel Arrabal-Polo et al.

Urology, 81(4), 731-737 (2013-02-05)

To analyze the effects of aminobisphosphonates and thiazides on renal lithogenic activity and bone mineral density in patients with recurring renal calcium lithiasis. A prospective cohort study with 3 years of clinical follow-up data was performed. The study included 2

Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice.

Mohammad S Khorasani et al.

Arthritis research & therapy, 17, 30-30 (2015-04-19)

Previous studies in animal models of osteoarthritis suggest that alendronate (ALN) has antiresorptive and chondroprotective effects, and can reduce osteophyte formation. However, these studies used non-physiologic injury methods, and did not investigate early time points during which bone is rapidly

[Pharmacological and clinical properties of alendronate sodium hydrate].

Tomohiro Ohta et al.

Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 120(6), 409-419 (2003-01-17)

Alendronate (alendronate sodium hydrate; Bonalon Tablet, 5 mg) is a nitrogen-containing bisphosphonate, which combines with the bone surface and reduces osteoclast-mediated bone resorption. It is a third-generation bisphosphonate compound, specifically distributed on the surface of bone resorption and taken into

Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.

Mattias Ulmner et al.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(1), 76-82 (2013-09-03)

To estimate the incidence of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) associated with the use of oral BPs and osteonecrosis of the jaw (ONJ) not associated with current or previous medication with a BP or radiotherapy to the head

Liquid chromatography-mass spectrometry analysis of five bisphosphonates in equine urine and plasma.

April S Y Wong et al.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 998-999, 1-7 (2015-07-06)

Bisphosphonates are used in the management of skeletal disorder in humans and horses, with tiludronic acid being the first licensed veterinary medicine in the treatment of lameness associated with degenerative joint disease. Bisphosphonates are prohibited in horseracing according to Article

Enhancement of bone consolidation in mandibular distraction osteogenesis: a contemporary review of experimental studies involving adjuvant therapies.

Paul Hong et al.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 66(7), 883-895 (2013-04-23)

One of the major disadvantages of mandibular distraction osteogenesis (MDO) is the prolonged time required for consolidation of the regenerate bone. The objective of the present study is to perform a contemporary review of various adjuvant therapies to enhance bone

Romosozumab in postmenopausal women with low bone mineral density.

Michael R McClung et al.

The New England journal of medicine, 370(5), 412-420 (2014-01-03)

Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a

Page 1 of 3